Aptus Pharma Peer Comparison
BSE: 544529
₹347.05
₹-7.05
(-1.99%)
As on 24-Sep-2026 11:31IST
Market cap
₹607 Cr
Revenue (TTM)
₹47 Cr
P/E Ratio
131.4
P/B Ratio
18.1
Div. Yield
0 %
Edit
| Aptus Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
607 | 37,494 | 27,393 | 26,981 | 28,411 |
Revenue (₹ Cr) |
47 | 3,564 | 1,936 | 1,462 | 9,205 |
Net Profit (₹ Cr) |
4.62 | 414.00 | 288.22 | 387.35 | -371.81 |
Net Margin (%) |
9.89 | 11.23 | 14.79 | 26.01 | -3.93 |
RoE (%) |
30.48 | 8.38 | 29.77 | 25.18 | -3.85 |
Price to Earnings |
131.45 | 91.67 | 95.04 | 69.86 | -- |
Price-To-Book |
18.05 | 7.45 | 20.41 | 15.64 | 3.55 |
Income Statement (₹ Cr)
| Aptus Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Operating Revenue
|
46.57 | 3,373.00 | 1,753.96 | 1,339.37 | 8,869.08 |
|
Total Income
|
46.71 | 3,510.00 | 1,762.66 | 1,380.95 | 9,111.51 |
|
Total Expenditure
|
39.12 | 2,747.00 | 1,354.69 | 858.97 | 7,976.59 |
|
EBITDA
|
7.45 | 626.00 | 399.26 | 480.40 | 892.49 |
|
Depreciation
|
0.41 | 227.00 | 45.26 | 35.99 | 831.24 |
|
EBIT
|
7.05 | 399.00 | 354.00 | 444.41 | 61.25 |
|
Interest
|
0.81 | 213.00 | 42.17 | 3.27 | 340.80 |
|
Other Income
|
0.13 | 137.00 | 8.70 | 41.59 | 242.43 |
|
Exceptional Items
|
-- | -85.00 | -- | -- | -196.14 |
|
Profit before Tax
|
6.37 | 238.00 | 320.53 | 482.73 | -176.06 |
|
Provision for Tax
|
1.75 | 39.00 | 73.80 | 126.36 | 149.88 |
|
Profit after Tax
|
4.62 | 199.00 | 246.74 | 356.37 | -325.94 |
Liabilities (₹ Cr)
| Aptus Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
23.35 | 4,940.00 | 1,288.82 | 1,653.56 | 8,162.62 |
|
Minority Interest
|
-- | 341.00 | 0.00 | 57.19 | -- |
|
Non-Current Liabilities
|
0.79 | 1,235.00 | 189.02 | 42.40 | 4,529.41 |
|
Current Liabilities
|
19.31 | 1,622.00 | 835.87 | 230.81 | 4,874.74 |
|
Total Liabilities
|
43.53 | 8,578.00 | 2,326.71 | 1,983.96 | 17,723.32 |
Assets (₹ Cr)
| Aptus Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
8.21 | 5,441.00 | 631.90 | 1,102.69 | 10,258.66 |
|
Current Assets
|
35.24 | 2,606.00 | 1,681.81 | 881.27 | 7,308.11 |
|
Total Assets
|
43.53 | 8,578.00 | 2,326.71 | 1,983.96 | 17,723.32 |
|
Total Debt*
|
7.18 | 2,125.00 | 259.37 | 26.49 | 5,495.48 |
|
Net Current Assets
|
15.93 | 984.00 | 845.94 | 650.46 | 2,433.37 |
|
Contingent Liabilities
|
-- | 768.26 | 19.09 | 17.25 | 95.72 |
Cashflow (₹ Cr)
| Aptus Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-5.60 | 390.00 | 205.05 | 292.17 | 1,652.60 |
|
Cash Flow from Investing Activities
|
-6.37 | -241.00 | -409.72 | -265.94 | -826.03 |
|
Cash from Financing Activities
|
7.79 | -54.00 | 283.07 | 4.10 | -38.98 |
|
Net Cash Inflow / Outflow
|
-4.19 | 95.00 | 78.39 | 30.33 | 787.59 |
Ratios
Profitability Ratios
| Aptus Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
30.01 | 6.79 | 29.22 | 32.42 | 1.24 |
|
ROE (%)
|
30.48 | 4.29 | 27.84 | 24.08 | -4.04 |
|
ROA (%)
|
14.15 | 2.53 | 13.11 | 20.17 | -1.98 |
|
EBIT Margin (%)
|
16.29 | 22.62 | 23.26 | 38.97 | 12.80 |
|
Net Margin (%)
|
9.89 | 5.67 | 14.00 | 25.81 | -3.58 |
|
Cash Profit Margin (%)
|
10.51 | 10.98 | 7.71 | 29.29 | 4.80 |
Growth Ratios
| Aptus Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
89.65 | 11.99 | 36.57 | 33.02 | -3.08 |
|
EBIT Growth (%)
|
53.97 | 67.69 | 52.29 | 109.63 | -28.15 |
|
Net Profit Growth (%)
|
49.05 | 449.12 | 83.64 | 122.15 | -457.66 |
|
EPS Growth (%)
|
443.21 | 553.20 | 71.44 | 348.92 | -456.91 |
|
Book Value Growth (%)
|
235.14 | 13.47 | 144.31 | 26.03 | 0.33 |
Valuation Ratios
| Aptus Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
20.74 | 89.54 | 51.69 | 58.79 | 0.00 |
|
Price / Book Value
|
10.26 | 3.87 | 10.14 | 12.69 | 2.24 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 0.19 | 0.10 | 0.00 |
|
EV/EBITDA
|
32.38 | 27.45 | 31.05 | 39.75 | 19.72 |
|
Market Cap (₹ Cr)
|
239.52 | 19,071.62 | 12,753.19 | 20,944.75 | 18,108.89 |
Solvency Ratios
| Aptus Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.31 | 0.43 | 0.21 | 0.02 | 0.68 |
|
Short term debt to equity ratio
|
0.28 | 0.09 | 0.05 | 0.02 | 0.09 |
|
Current Ratio
|
1.83 | 1.61 | 2.01 | 3.82 | 1.50 |
|
Quick Ratio
|
1.12 | 1.06 | 1.14 | 2.82 | 0.87 |
|
Interest Coverage
|
8.92 | 2.12 | 8.60 | 148.71 | 0.48 |
Operating Efficiency Ratios
| Aptus Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
40.28 | 17.43 | 29.00 | 27.07 | 24.33 |
|
Asset Turnover
|
1.47 | 0.49 | 2.01 | 0.76 | 0.64 |
|
Receivable days
|
93.10 | 58.75 | 40.13 | 88.98 | 78.20 |
|
Inventory Days
|
78.71 | 75.82 | 60.29 | 56.04 | 93.30 |
|
Payable days
|
80.80 | 186.21 | 232.47 | 99.95 | 226.14 |
|
Cash Conversion Cycle
|
91.00 | -51.64 | -132.04 | 45.07 | -54.64 |
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
